Evidence map›Paper›PMID 32222038›Full record

ArticleImmunity, inflammation and disease2020

Burden of asthma exacerbations and health care utilization in pediatric patients with asthma in the US and England.

Mugdha Gokhale, Takako Hattori, Lee Evitt, Warren Lenney, Beth Nordstrom, Jenna Collins, Anna Schultze, Melissa K Van Dyke

Abstract readComparative Study
In one paragraph

Article in Immunity, inflammation and disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Cumulative genetic risk for asthma contributes to disease severity in children with asthma.The journal of allergy and clinical immunology. Global · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mugdha GokhaleEpidemiology, GlaxoSmithKline, Upper Providence, Pennsylvania.
Takako HattoriGlobal Respiratory Franchise, GlaxoSmithKline, London, UK.
Lee EvittValue Evidence and Outcomes, GlaxoSmithKline, London, UK.
Warren LenneyGlobal Medical Expert, GlaxoSmithKline, London, UK.
Beth NordstromData Analytics, Evidera, Waltham, Massachusetts.ORCID 0000-0003-1743-9610
Jenna CollinsData Analytics, Evidera, Waltham, Massachusetts.
Anna SchultzeReal World Evidence, Evidera, London, UK.
Melissa K Van DykeEpidemiology, GlaxoSmithKline, Upper Providence, Pennsylvania.ORCID 0000-0001-7246-2093

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData on asthma burden in pediatric patients are limited; this real-world study investigated exacerbation frequency and health care resource utilization (HCRU) in pediatric asthma patients from the US and England.

methodsData from pediatric patients (aged 6-17 years) in the Optum claims database (US) or Clinical Practice Research Datalink with linkage to Hospital Episode Statistics (England) were analyzed. Patients were categorized into four hierarchical groups: treated asthma (patients with ≥1 baseline asthma medication), severe asthma (plus Global Initiative for Asthma Step 4/5), severe refractory asthma ([SRA] plus ≥2 baseline severe asthma exacerbations), and eosinophilic SRA (SRA plus blood eosinophil count ≥150 cells/µL). Exacerbation frequency and HCRU during the 12 months postindex were described.

resultsOf 151 549 treated asthma patients in the US, 18 086 had severe asthma, 2099 SRA, and 109 eosinophilic SRA. There were 32 893 treated asthma patients in England, of whom 2711 had severe asthma, 265 SRA, and 8 eosinophilic SRA. In the 12 months postindex, ≥1 exacerbation occurred in 12.4% and 10.8% of patients with severe asthma, and 32.6% and 42.6% with SRA in the US and England, respectively. The proportions of patients with ≥1 asthma hospitalization in the 30 days after the first asthma exacerbation were 2.7% and 4.4% (treated), 3.5% and 8.2% (severe asthma), and 6.0% and 16.8% (SRA) in the US and England, respectively.

conclusionThis study provides insights into current asthma management practices in the US and England and indicates that some patients with severe disease have an unmet need for effective management.

Indexed as

Disease ProgressionAdolescentAnti-Asthmatic AgentsAsthmaChildCost of IllnessDatabases, FactualEnglandFemaleHospitalizationHumansMaleOutcome Assessment, Health CarePatient Acceptance of Health CareRetrospective StudiesSeverity of Illness IndexAnti-Asthmatic Agentsasthmahealth carepediatrics

Identifiers

PMID32222038
PMCPMC7212194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.